TY - JOUR
TI - Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial
Stiffness and Inflammation in Coronary Artery Disease Patients Under
Clopidogrel Treatment
AU - Siasos, Gerasimos
AU - Zaromitidou, Marina
AU - Oikonomou, Evangelos and
AU - Mourouzis, Konstantinos
AU - Tsalamandris, Sotiris
AU - Kioufis, Stamatios
AU - and Kokkou, Eleni
AU - Vavuranakis, Manolis
AU - Zografos, Theodoros and
AU - Antonopoulos, Alexis
AU - Dimitropoulos, Stathis
AU - Stefanadis,
AU - Christodoulos
AU - Papavassiliou, Athanasios G.
AU - Tousoulis, Dimitris
JO - Current Pharmaceutical Design
PY - 2015
VL - 21
TODO - 34
SP - 5041-5046
PB - BENTHAM SCIENCE PUBL LTD
SN - 1381-6128
TODO - 10.2174/1381612821666150827124459
TODO - Arterial stiffness; atherosclerosis; clopidogrel; coronary artery
disease; endothelial function; inflammation; polymorphisms; vascular
endothelium
TODO - Background: Clopidogrel’s ability to inhibit platelet function
determined its clinical usefulness. The role of CYP2C19*2 genotype on
antiplatelet treatment is recently under question. Arterial wall
properties and inflammation are key players in atherosclerosis
development. Hence, we evaluated the impact of CYP2C19*2 genetic
polymorphism on endothelial function, arterial stiffness and
inflammation in coronary artery disease (CAD) patients receiving
clopidogrel treatment.
Methods and Results: In this study we enrolled 408 consecutive patients
with stable CAD under dual antiplatelet therapy (clopidogrel 75mg/day,
aspirin 100mg/day), 30 days after percutaneous coronary intervention.
Measurement of flow-mediated dilation (FMD) of the brachial artery was
used to evaluate endothelial function. Carotid-femoral pulse wave
velocity (PWV) and augmentation index (AIx) was measured to estimate
arterial stiffness. Real time polymerase chain reaction was used for the
genotyping of CYP2C19*2. Levels of tumor necrosis factor alpha (TNF-a)
and interleukin 6 (IL-6) were measured with ELISA. We found no
difference in basic clinical and demographic characteristics nor in FMD,
PWV, AIx and inflammatory status (p=NS for all) between CYP2C19
homozygotes for the wild type; carriers of reduced function allele and
homozygotes for the reduced function allele.
Conclusion: CYP2C19*2 loss of action polymorphism causes no impact on
vascular function and inflammatory status in stable CAD patients
receiving clopidogrel treatment.
ER -